Dianthus Therapeutics income statement data for the quarter ended Dec 2025. This income statement covers 35 quarters of results from Jun 2017 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2017 | Sep2017 | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||||||||||||
| Revenue | 1.17M | 1.18M | 0.50M | 1.00M | 0.92M | 0.46M | 0.87M | 1.86M | 2.17M | 1.33M | 1.16M | 0.19M | 0.40M | ||||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 11.73M | 11.13M | 10.79M | 13.11M | 16.55M | 11.60M | 7.22M | 9.83M | 5.85M | 10.25M | 7.96M | 8.78M | 13.08M | 18.07M | 25.54M | 31.21M | 27.00M | 26.25M | 32.49M | ||||||||||||||||
| Selling, General & AdministrativeSG&A | 6.97M | 6.48M | 7.45M | 7.03M | 7.29M | 6.48M | 2.21M | 2.04M | 2.31M | 2.49M | 8.72M | 4.63M | 5.64M | 6.00M | 6.53M | 6.83M | 7.34M | 8.87M | 8.20M | ||||||||||||||||
| Restructuring CostsRestructuring | 18.00M | 1.92M | |||||||||||||||||||||||||||||||||
| Other Operating ExpensesOther Opex | -18.00M | -1.92M | -4.79M | ||||||||||||||||||||||||||||||||
| Operating ExpensesOpex | 18.70M | 17.61M | 18.25M | 20.14M | 23.83M | 18.08M | 9.43M | 11.87M | 8.16M | 12.74M | 16.68M | 13.41M | 18.72M | 24.07M | 32.07M | 33.24M | 34.34M | 35.12M | 40.68M | ||||||||||||||||
| Operating IncomeOp. Inc | -18.70M | -17.61M | -18.25M | -20.14M | -23.83M | -18.08M | -8.25M | -10.69M | -7.68M | -11.78M | -15.76M | -12.96M | -17.84M | -22.20M | -29.90M | -31.92M | -33.18M | -34.93M | -40.29M | ||||||||||||||||
| EBIT | -18.70M | -17.61M | -18.25M | -20.14M | -23.83M | -18.08M | -8.25M | -10.69M | -7.68M | -11.78M | -15.76M | -12.96M | -17.84M | -22.20M | -29.90M | -31.92M | -33.18M | -34.93M | -40.29M | ||||||||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 1.21M | 0.68M | 0.82M | 0.85M | 0.88M | 0.81M | 0.42M | 0.64M | 0.61M | 0.69M | 1.03M | 2.44M | -0.07M | -0.01M | 4.45M | 3.99M | 0.16M | 3.40M | 3.66M | ||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.06M | -0.02M | -0.01M | -0.03M | -0.02M | -0.03M | -0.11M | -0.08M | -0.05M | -0.38M | -0.10M | -0.11M | -0.36M | ||||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | 0.47M | 0.58M | 0.59M | 0.64M | 1.00M | 2.39M | 4.10M | 4.60M | 4.73M | 3.48M | 3.67M | 3.30M | 3.52M | ||||||||||||||||||||||
| Net income details | |||||||||||||||||||||||||||||||||||
| EBT | -17.49M | -16.93M | -17.43M | -19.29M | -22.95M | -17.27M | -7.84M | -10.05M | -7.08M | -11.09M | -14.73M | -10.51M | -17.92M | -22.21M | -25.45M | -27.93M | -33.01M | -31.52M | -36.63M | ||||||||||||||||
| Profit After TaxPAT | -17.49M | -16.93M | -17.43M | -19.30M | -4.88M | -5.70M | -7.93M | -10.13M | -7.09M | -11.14M | -14.76M | -10.60M | -13.75M | -17.61M | -25.17M | -28.47M | -29.51M | -31.80M | -36.77M | ||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -17.49M | -16.93M | -17.43M | -19.29M | -22.95M | -17.27M | -7.84M | -10.05M | -7.08M | -11.09M | -14.73M | -10.51M | -17.92M | -22.21M | -25.45M | -27.93M | -33.01M | -31.52M | -36.63M | ||||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -17.49M | -16.93M | -17.43M | -19.29M | -22.95M | -17.27M | -7.84M | -10.05M | -7.08M | -11.09M | -14.73M | -10.51M | -17.92M | -22.21M | -25.45M | -27.93M | -33.01M | -31.52M | -36.63M | ||||||||||||||||
| Income towards Parent CompanyParent Net Inc | -17.49M | -16.93M | -17.43M | -19.29M | -22.95M | -17.27M | -7.84M | -10.05M | -7.08M | -11.09M | -14.73M | -10.51M | -17.92M | -22.21M | -25.45M | -27.93M | -33.01M | -31.52M | -36.63M | ||||||||||||||||
| Preferred Dividend PaymentsPref Dividends | |||||||||||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -17.49M | -16.93M | -17.43M | -19.29M | -22.95M | -17.27M | -7.84M | -10.05M | -7.08M | -11.09M | -14.73M | -10.51M | -17.92M | -22.21M | -25.45M | -27.93M | -33.01M | -31.52M | -36.63M | ||||||||||||||||
| Additional items | |||||||||||||||||||||||||||||||||||
| EPS (Basic) | -5.76 | -5.04 | -4.76 | -5.62 | -6.24 | -4.70 | -2.12 | -2.71 | -1.87 | -2.93 | -3.77 | -2.04 | -0.70 | -0.65 | -0.74 | -0.84 | -0.92 | -0.88 | -0.97 | ||||||||||||||||
| EPS (Diluted) | -5.76 | -5.04 | -4.76 | -5.62 | -6.24 | -4.70 | -2.12 | -2.71 | -1.87 | -2.93 | -3.77 | -2.04 | -0.70 | -0.65 | -0.74 | -0.84 | -0.92 | -0.88 | -0.97 | ||||||||||||||||
| Shares Outstanding | 3.04M | 3.36M | 3.66M | 3.43M | 3.67M | 3.68M | 3.70M | 3.71M | 3.79M | 3.79M | 3.91M | 5.15M | 25.67M | 34.23M | 34.24M | 33.31M | 35.79M | 35.82M | 37.79M | 37.79M | |||||||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 3.04M | 3.36M | 3.66M | 3.43M | 3.67M | 3.68M | 3.70M | 3.71M | 3.79M | 3.79M | 3.91M | 5.15M | 25.67M | 34.23M | 34.24M | 33.31M | 35.79M | 35.82M | 37.79M | 37.79M | |||||||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 3.04M | 3.66M | 3.67M | 3.67M | 3.67M | 3.67M | 3.78M | 3.79M | 3.79M | 3.79M | 3.91M | 5.15M | 29.35M | 29.35M | 29.37M | 31.12M | 32.13M | 32.18M | 42.85M | ||||||||||||||||
| EBITDA | -18.70M | -17.61M | -18.25M | -20.14M | -23.83M | -18.08M | -8.25M | -10.69M | -7.68M | -11.78M | -15.76M | -12.96M | -17.84M | -22.20M | -29.90M | -31.92M | -33.18M | -34.93M | -40.29M |